|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.30 EUR | +1.26% |
|
-1.04% | +2.78% |
| 03:04am | Bayer's New Drug Application for Stroke Prevention Treatment Secures US, Japanese Nods | MT |
| 02:40am | Bayer: U.S. FDA grants priority review for asundexian in patients after ischaemic strokes | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 44.08B | 50.74B | 47.64B | 46.61B | 45.58B | |||||
Total Revenues | 44.08B | 50.74B | 47.64B | 46.61B | 45.58B | |||||
Cost of Goods Sold, Total | 17.04B | 18.89B | 19.75B | 20.83B | 18.53B | |||||
Gross Profit | 27.04B | 31.85B | 27.89B | 25.78B | 27.05B | |||||
Selling General & Admin Expenses, Total | 14.61B | 16.04B | 14.71B | 16.76B | 16.02B | |||||
R&D Expenses | 5.33B | 6.17B | 5.84B | 5.97B | 5.65B | |||||
Other Operating Expenses | 27M | 528M | -457M | -78M | 262M | |||||
Other Operating Expenses, Total | 19.96B | 22.73B | 20.09B | 22.66B | 21.94B | |||||
Operating Income | 7.07B | 9.12B | 7.8B | 3.12B | 5.11B | |||||
Interest Expense, Total | -1.29B | -1.06B | -1.13B | -1.95B | -1.93B | |||||
Interest And Investment Income | 346M | 379M | 484M | 521M | 471M | |||||
Net Interest Expenses | -940M | -679M | -650M | -1.42B | -1.46B | |||||
Income (Loss) On Equity Invest. | 49M | -450M | -335M | -295M | -70M | |||||
Currency Exchange Gains (Loss) | -385M | -219M | -449M | -203M | -169M | |||||
Other Non Operating Income (Expenses) | 23M | -844M | -788M | 1.46B | 1.46B | |||||
EBT, Excl. Unusual Items | 5.82B | 6.93B | 5.58B | 2.66B | 4.87B | |||||
Restructuring Charges | - | - | - | - | - | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | - | -734M | -6.69B | -3.26B | - | |||||
Gain (Loss) On Sale Of Investments | -39M | -150M | -11M | -3M | -20M | |||||
Gain (Loss) On Sale Of Assets | 86M | - | - | - | - | |||||
Asset Writedown | 132M | 1.69B | 152M | 207M | 469M | |||||
Insurance Settlements | - | - | - | - | - | |||||
Legal Settlements | -3.69B | -791M | -889M | -548M | -7.85B | |||||
Other Unusual Items | -262M | -2.28B | 240M | -1.38B | -600M | |||||
EBT, Incl. Unusual Items | 2.05B | 4.67B | -1.62B | -2.33B | -3.13B | |||||
Income Tax Expense | 1.02B | 504M | 1.32B | 212M | 466M | |||||
Earnings From Continuing Operations | 1.02B | 4.17B | -2.94B | -2.55B | -3.6B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 1.02B | 4.17B | -2.94B | -2.55B | -3.6B | |||||
Minority Interest | -22M | -16M | 1M | -6M | -25M | |||||
Net Income - (IS) | 1B | 4.15B | -2.94B | -2.55B | -3.62B | |||||
Net Income to Common Incl Extra Items | 1B | 4.15B | -2.94B | -2.55B | -3.62B | |||||
Net Income to Common Excl. Extra Items | 1B | 4.15B | -2.94B | -2.55B | -3.62B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1.02 | 4.22 | -2.99 | -2.6 | -3.68 | |||||
Basic EPS - Continuing Operations | 1.02 | 4.22 | -2.99 | -2.6 | -3.68 | |||||
Basic Weighted Average Shares Outstanding | 982M | 982M | 982M | 982M | 982M | |||||
Net EPS - Diluted | 1.02 | 4.22 | -2.99 | -2.6 | -3.68 | |||||
Diluted EPS - Continuing Operations | 1.02 | 4.22 | -2.99 | -2.6 | -3.68 | |||||
Diluted Weighted Average Shares Outstanding | 982M | 982M | 982M | 982M | 982M | |||||
Normalized Basic EPS | 3.68 | 4.39 | 3.55 | 1.68 | 3.07 | |||||
Normalized Diluted EPS | 3.68 | 4.39 | 3.55 | 1.68 | 3.07 | |||||
Dividend Per Share | 2 | 2.4 | 0.11 | 0.11 | 0.11 | |||||
Payout Ratio | 199.3 | 47.83 | -80.89 | -4.23 | -2.98 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 8.34B | 12.7B | 11.33B | 6.81B | 8.87B | |||||
EBITA | 7.19B | 11.52B | 10.12B | 5.57B | 7.57B | |||||
EBIT | 7.07B | 9.12B | 7.8B | 3.12B | 5.11B | |||||
EBITDAR | 8.63B | 13.15B | 11.79B | 7.27B | 9.18B | |||||
Effective Tax Rate - (Ratio) | 50.05 | 10.79 | -81.49 | -9.08 | -14.89 | |||||
Current Domestic Taxes | 604M | 912M | 359M | 58M | -53M | |||||
Current Foreign Taxes | 1.02B | 1.66B | 884M | 887M | 1.05B | |||||
Total Current Taxes | 1.63B | 2.57B | 1.24B | 945M | 995M | |||||
Total Deferred Taxes | -602M | -2.07B | 78M | -733M | -529M | |||||
Normalized Net Income | 3.61B | 4.31B | 3.49B | 1.65B | 3.02B | |||||
Interest Capitalized | 30M | 38M | 53M | 61M | 56M | |||||
Interest on Long-Term Debt | - | - | 72M | 77M | 77M | |||||
Non-Cash Pension Expense | 62M | 78M | 125M | 87M | 49M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 12.27B | 13.55B | 12.57B | 13.09B | 12.4B | |||||
General and Administrative Expenses | 2.26B | 2.49B | 2.14B | 2.18B | 2.11B | |||||
Research And Development Expense From Footnotes | 5.72B | 7.4B | 5.63B | 6.39B | 5.98B | |||||
Net Rental Expense, Total | 286M | 447M | 461M | 468M | 306M | |||||
Imputed Operating Lease Interest Expense | 72.87M | 94.98M | 101M | 175M | 124M | |||||
Imputed Operating Lease Depreciation | 213M | 352M | 360M | 293M | 182M | |||||
Stock-Based Comp., Other (Total) | 238M | 365M | 153M | 58M | 440M | |||||
Total Stock-Based Compensation | 238M | 365M | 153M | 58M | 440M |
- Stock Market
- Equities
- BAYN Stock
- Financials Bayer AG
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















